Neurocrine Biosciences
NBIX
#1452
Rank
A$21.10 B
Marketcap
A$207.67
Share price
-0.19%
Change (1 day)
-1.32%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$10.41

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$10.02. In 2025 the company made an earnings per share (EPS) of A$6.85 an increase over its 2024 EPS that were of A$4.80.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$10.4151.89%
2025A$6.8542.6%
2024A$4.8033.07%
2023A$3.6157.76%
2022A$2.2969.47%
2021A$1.35-78.21%
2020A$6.20990%
2019A$0.5781.82%
2018A$0.31-113.5%
2017A-$2.320.62%
2016A-$2.3057.28%
2015A-$1.4625.61%
2014A-$1.1718.84%
2013A-$0.98-1085.71%
2012A$0.09950

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.08-89.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$5.08-49.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$42.48 323.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.07-89.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.89-128.79%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$6.87-31.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$10.73-207.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.67-73.39%๐Ÿ‡ฌ๐Ÿ‡ง UK